Dyslipidemia, Vascular Atheroma and Statins

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Medical Imaging

Background:

• Dyslipidemia is a key driver of atherosclerotic coronary artery disease.
• Atheroma regression using lipid-lowering agents is a potential therapeutic strategy but requires further investigation.
• Current understanding of atheroma regression is limited, necessitating more research.

Purpose of the Study:

• To review the current understanding and ongoing debates surrounding atheroma regression in atherosclerotic coronary artery disease.
• To explore the complexities of assessing plaque regression, including imaging modalities and time courses.
• To discuss the role of statins and other agents in achieving atheroma regression and identify areas for future research.

Main Methods:

• This narrative review synthesizes existing literature on dyslipidemia, atherosclerosis, and lipid-lowering therapies.
• It examines evidence related to the assessment of atheroma regression using various imaging techniques.
• The review discusses clinical considerations, including statin types, combination therapies, and patient-specific factors.

Main Results:

• Lipid-lowering agents, particularly statins, demonstrate potential for inducing regression of atherosclerotic atheroma.
• Significant questions remain regarding optimal assessment methods, treatment duration, and the uniformity of regression across arterial territories.
• The impact of patient demographics (age, gender, ethnicity) on regression requires further elucidation.

Conclusions:

• Atheroma regression is a promising but complex therapeutic goal in managing atherosclerotic coronary artery disease.
• Further randomized controlled studies employing evidence-based diagnostic tools are essential to refine treatment strategies.
• Personalized approaches considering patient factors and optimal therapeutic regimens are needed to maximize the benefits of lipid-lowering therapies for atheroma regression.